HC Wainwright Brokers Raise Earnings Estimates for MIST

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Stock analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a note issued to investors on Tuesday, July 15th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.10) for the quarter, up from their previous forecast of ($0.12). HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.61) EPS, FY2026 earnings at ($0.42) EPS and FY2027 earnings at ($0.49) EPS.

A number of other equities research analysts also recently weighed in on MIST. Cowen downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Securities downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $7.00.

Milestone Pharmaceuticals Stock Down 4.2%

Milestone Pharmaceuticals stock traded down $0.07 during mid-day trading on Thursday, hitting $1.58. The company's stock had a trading volume of 1,735,891 shares, compared to its average volume of 1,135,121. The firm's 50 day moving average is $1.68 and its 200 day moving average is $1.67. The company has a market cap of $84.47 million, a PE ratio of -2.03 and a beta of 0.96. The company has a debt-to-equity ratio of 4.06, a current ratio of 4.67 and a quick ratio of 4.67. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12).

Institutional Trading of Milestone Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bay Rivers Group bought a new stake in Milestone Pharmaceuticals in the second quarter valued at approximately $28,000. Propel Bio Management LLC bought a new stake in Milestone Pharmaceuticals in the first quarter valued at approximately $1,161,000. Walleye Capital LLC bought a new stake in Milestone Pharmaceuticals in the first quarter valued at approximately $74,000. XTX Topco Ltd raised its stake in Milestone Pharmaceuticals by 52.7% in the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock valued at $42,000 after buying an additional 17,950 shares during the period. Finally, Toronto Dominion Bank bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth approximately $1,770,000. Institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.